Stockreport

OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain [Yahoo! Finance]

OKYO Pharma Limited - American Depositary Shares  (OKYO) 
PDF The initial trial of OK-101 to treat NCP is designed as a randomized, placebo-controlled, double-masked Phase 2 clinical trial and is planned to begin in 2Q 2024 NCP [Read more]